Clinicopathological characteristics and prognosis of gastric signet ring cell carcinoma

Table 1 General characteristics of Surveillance, Epidemiology and End Results and validation data sets

Variable	SEER data set (%), n = 5200	Validation data set (%), n = 603
Age (yr)
< 40	200 (3.85)	41 (6.80)
40-60	1389 (26.71)	313 (51.91)
60-80	2690 (51.73)	236 (39.14)
> 80	921 (17.71)	13 (2.15)
Sex
Male	2933 (56.40)	423 (70.15)
Female	2267 (43.60)	180 (29.85)
Race
White	2947 (56.67)
Black	830 (15.96)
Black-AI	52 (1.00)
Black-API	1371 (26.37)
T stage
T1a	597 (11.48)	247 (40.96)
T1b	708 (13.62)
T2	693 (13.33)	70 (11.61)
T3	1697 (32.63)	8 (1.33)
T4a	1155 (22.21)	278 (46.10)
T4b	350 (6.73)
N stage
N0	2233 (42.94)	266 (44.11)
N1	951 (18.29)	184 (30.52)
N2	855 (16.44)	89 (14.76)
N3	1161 (22.33)	64 (10.61)
AJCC stage
I	1580 (30.38)	262 (43.45)
II	1449 (27.87)	71 (11.77)
III	2171 (41.75)	270 (44.78)
Radiotherapy
Yes	1416 (27.23)	16 (2.66)
No	3784 (72.77)	587 (97.34)
Chemotherapy
Yes	2599 (49.98)	445 (73.80)
No	2601 (50.02)	158 (26.20)
Tumor size (cm)
< 2	820 (15.77)
2-5	2198 (42.27)	94 (15.59)
> 5	1700 (32.69)	393 (65.17)
NA	482 (9.27)	116 (19.24)
Histology
SRC	1326 (25.50)	84 (13.93)
Differentiated	1550 (29.81)	241 (39.97)
Undifferentiated	2324 (44.69)	278 (46.10)

SEER: Surveillance, Epidemiology and End Results; SRC: Signet ring cell carcinoma; API: Asian Pacific Islanders; AI: American Indians.